Navigating the New Era of HER2+ Breast Cancer Care: 2025 Conference Highlights

Balancing efficacy with quality of life is now central to HER2+ breast cancer treatment. From omitting carboplatin in selected stage II patients to using the HER2DX assay to personalize care, precision medicine is making therapy increasingly tailored to each patient’s tumor biology. Join us at this year’s conference to explore the next wave of clinical advances and discuss these evolving strategies live.